A Two-Part Study in Japanese Patients With Advanced or Metastatic NSCLC. Open-Label Phase I to Assess the Safety & Tolerability of AZD2171 in Combination With Pac/Carb, Then a Phase II, Randomised, Double-Blind Study to Assess the Efficacy of AZD2171 Alone and in Combination With AZD2171 and Pac/Carb
Phase 1
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Registration Number
- JPRN-jRCT2080220478
- Lead Sponsor
- AstraZeneca
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Ages Eligible for Study: 18 Years and older
Genders Eligible for Study: Both
Inclusion Criteria:
- Having histologically or cytologically confirmed NSCLC
- Patients with previously untreated advanced/metastatic (Stage IIIB/IV) or postsurgery recurrent NSCLC
- WHO performance status 0-1
Exclusion Criteria
- Untreated unstable brain or meningeal metastases
- Patient with inappropriate laboratory tests values
- Patient with poorly controlled hypertension
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method